86 related articles for article (PubMed ID: 6317554)
1. Protracted effect of converting-enzyme inhibition on the rat's response to intraarterial bradykinin.
Lindsey CJ; de Paula UM; Paiva AC
Hypertension; 1983; 5(6 Pt 3):V134-7. PubMed ID: 6317554
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I.
Greco AJ; Master RG; Fokin A; Baber SR; Kadowitz PJ
Can J Physiol Pharmacol; 2006 Nov; 84(11):1163-75. PubMed ID: 17218981
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats.
Lima CV; Paula RD; Resende FL; Khosla MC; Santos RA
Hypertension; 1997 Sep; 30(3 Pt 2):542-8. PubMed ID: 9322979
[TBL] [Abstract][Full Text] [Related]
4. Role of kinins in the renal response to enalaprilat in normotensive and hypertensive rats.
Fitzgibbon WR; Jaffa AA; Mayfield RK; Ploth DW
Hypertension; 1996 Feb; 27(2):235-44. PubMed ID: 8567046
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats.
Paula RD; Lima CV; Khosla MC; Santos RA
Hypertension; 1995 Dec; 26(6 Pt 2):1154-9. PubMed ID: 7498987
[TBL] [Abstract][Full Text] [Related]
6. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.
Unger T; Ganten D; Lang RE; Schölkens BA
J Cardiovasc Pharmacol; 1984; 6(5):872-80. PubMed ID: 6209494
[TBL] [Abstract][Full Text] [Related]
7. Alterations in responses to bradykinin, angiotensin I, and angiotensin II during the induction phase of one-kidney, one-wrapped hypertension and associated arterial disease in rabbits.
Campbell WG; Donohue JA; Duket LH
Am J Pathol; 1980 Feb; 98(2):457-84. PubMed ID: 6243872
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of the new non-sulfhydryl angiotensin converting enzyme inhibitor N-[8-amino-1(S)-carboxyoctyl]-L-alanyl-L-proline.
Shirota M; Kajiwara Y; Iijima M; Kitabatake K
Arzneimittelforschung; 1990 May; 40(5):515-9. PubMed ID: 2166521
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of depressor responses to arachidonic acid by angiotensin converting enzyme inhibitors in the rat.
Hui SC; Dai S; Ogle CW
Clin Exp Pharmacol Physiol; 1984; 11(6):621-5. PubMed ID: 6100239
[TBL] [Abstract][Full Text] [Related]
11. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
12. Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats.
Carvalho MB; Duarte FV; Faria-Silva R; Fauler B; da Mata Machado LT; de Paula RD; Campagnole-Santos MJ; Santos RA
Hypertension; 2007 Oct; 50(4):762-7. PubMed ID: 17664388
[TBL] [Abstract][Full Text] [Related]
13. Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models.
Tokioka T; Shibasaki M; Fujimori A; Matsuda-Satoh Y; Uchida W; Inagaki O; Yanagisawa I
Biol Pharm Bull; 2000 Feb; 23(2):174-81. PubMed ID: 10706380
[TBL] [Abstract][Full Text] [Related]
14. Kinin receptors of the central nervous system of spontaneously hypertensive rats related to the pressor response to bradykinin.
Martins DT; Fior DR; Nakaie CR; Lindsey CJ
Br J Pharmacol; 1991 Aug; 103(4):1851-6. PubMed ID: 1655143
[TBL] [Abstract][Full Text] [Related]
15. Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats.
Stanziola L; Greene LJ; Santos RA
Am J Hypertens; 1999 Oct; 12(10 Pt 1):1021-9. PubMed ID: 10560789
[TBL] [Abstract][Full Text] [Related]
16. Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats.
Schiffrin EL; Gutkowska J; Thibault G; Genest J
Can J Physiol Pharmacol; 1984 Jan; 62(1):116-23. PubMed ID: 6143602
[TBL] [Abstract][Full Text] [Related]
17. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
18. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist.
Benetos A; Gavras H; Stewart JM; Vavrek RJ; Hatinoglou S; Gavras I
Hypertension; 1986 Nov; 8(11):971-4. PubMed ID: 3021624
[TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin.
Pham I; Gonzalez W; Doucet J; Fournie-Zaluski MC; Roques BP; Michel JB
Eur J Pharmacol; 1996 Feb; 296(3):267-76. PubMed ID: 8904078
[TBL] [Abstract][Full Text] [Related]
20. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
